On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Guide to the presentation
- Inflammation, an inducer and amplifier of diseases
- Mechanisms contributing to fatty streak formation
- Mechanisms contributing to lesion progression
- Mechanisms contributing to unstable lesions
- Risk factors for the development of atherosclerosis
- Risk factors and their relationship to inflammation
- Induction of inflammatory genes
- Toll like receptors and microbial pathogens
- Toll like receptors and endogenous ligands
- TLR4 and its roll in atherosclerosis
- Modulation of atherosclerosis in mice by TLR2
- Summary: inflammation and atherosclerosis
- TLR targets in the nucleus
- Induction of inflammatory response genes by LPS
- NCoR co-repressor complexes
- Conforming the NCoR complex model
- NCoR complex and signaling pathways
- Transcriptional control of inflammatory responses
- Nuclear receptor superfamily
- Transcriptional activities of nuclear receptors
- Regulation of the nuclear receptor expression
- Dexamethasone inhibition
- Glucocorticoid receptor repression
- Repression of LPS-responsive genes
- Nuclear receptors and inflammatory responses
- PPAR-gamma - structure, function and ligands
- PPAR-gamma expression in macrophages
- PPAR-gamma agonists
- PPAR-gamma ligands and foam cell formation
- Rosiglitazone inhibition
- PPAR-gamma ligands and atherosclerotic lesions
- Effect of Rosiglitazone on markers of inflammation
- NCoR SUMOylation-dependent mechanism
- NCoR and PPAR-gamma repression of iNOS
- NCoR, PPAR-gamma and iNOS
- Effects of TZDs on cardiovascular risk factors
- Adverse effects of TZDs
- PPAR-gamma-specific ligands summary
- Future prospects
- Acknowledgements
Topics Covered
- Nuclear receptors comprise a superfamily of ligand- and signal-dependent transcription factors that regulate diverse aspects of reproduction, development, metabolism and immunity
- Recent studies have demonstrated that a subset of nuclear receptors can co-ordinately regulate aspects of inflammation and metabolism that impact on the development of atherosclerosis and type 2 diabetes by inhibiting transcriptional responses to toll like receptors
- The nuclear receptor co-repressor NCoR plays a key role in maintaining inflammatory response genes in a repressed state under basal conditions
- PPARg inhibits inflammatory responses by preventing the removal of NCoR from target genes
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Glass, C. (2009, May 31). Nuclear receptors at the crossroads of inflammation and atherosclerosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/DZYQ8098.Export Citation (RIS)
Publication History
- Published on May 31, 2009
Financial Disclosures
- Prof. Christopher Glass has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Hide